IL228871A0 - Rapid processing modified alpha glucosidase - Google Patents

Rapid processing modified alpha glucosidase

Info

Publication number
IL228871A0
IL228871A0 IL228871A IL22887113A IL228871A0 IL 228871 A0 IL228871 A0 IL 228871A0 IL 228871 A IL228871 A IL 228871A IL 22887113 A IL22887113 A IL 22887113A IL 228871 A0 IL228871 A0 IL 228871A0
Authority
IL
Israel
Prior art keywords
acid alpha
accelerated processing
alpha glucosidase
modified acid
modified
Prior art date
Application number
IL228871A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL228871(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL228871A0 publication Critical patent/IL228871A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2408Glucanases acting on alpha -1,4-glucosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102Alpha-glucosidase (3.2.1.20)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL228871A 2011-04-22 2013-10-14 Rapid processing modified alpha glucosidase IL228871A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478336P 2011-04-22 2011-04-22
PCT/US2012/034479 WO2012145644A1 (en) 2011-04-22 2012-04-20 Modified acid alpha glucosidase with accelerated processing

Publications (1)

Publication Number Publication Date
IL228871A0 true IL228871A0 (en) 2013-12-31

Family

ID=46000406

Family Applications (1)

Application Number Title Priority Date Filing Date
IL228871A IL228871A0 (en) 2011-04-22 2013-10-14 Rapid processing modified alpha glucosidase

Country Status (24)

Country Link
US (1) US20140186326A1 (OSRAM)
EP (1) EP2699676A1 (OSRAM)
JP (2) JP2014513952A (OSRAM)
KR (1) KR20140037082A (OSRAM)
CN (1) CN103797115A (OSRAM)
AU (1) AU2012245280A1 (OSRAM)
BR (1) BR112013026976A2 (OSRAM)
CA (1) CA2833371A1 (OSRAM)
CL (1) CL2013003010A1 (OSRAM)
CO (1) CO6811810A2 (OSRAM)
CR (1) CR20130555A (OSRAM)
EC (1) ECSP13013036A (OSRAM)
GT (1) GT201300252A (OSRAM)
IL (1) IL228871A0 (OSRAM)
MA (1) MA35125B1 (OSRAM)
MX (1) MX2013012345A (OSRAM)
NI (1) NI201300110A (OSRAM)
PE (1) PE20140617A1 (OSRAM)
PH (1) PH12013502149A1 (OSRAM)
RU (1) RU2013151875A (OSRAM)
SG (2) SG194486A1 (OSRAM)
TN (1) TN2013000427A1 (OSRAM)
WO (1) WO2012145644A1 (OSRAM)
ZA (1) ZA201307696B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1220980A1 (zh) 2013-02-20 2017-05-19 Valerion Therapeutics, Llc 用於治疗庞贝氏症的方法和组合物
MY186336A (en) 2014-09-30 2021-07-13 Amicus Therapeutics Inc Highly potent acid alpha-glucosidase with enhanced carbohydrates
HK1253529A1 (zh) * 2015-11-06 2019-06-21 Biomarin Pharmaceutical Inc. 用於检测中和溶酶体酶的摄取的抗体或其它因子的基於细胞的测定
CA3010205A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
IL301319A (en) 2016-03-30 2023-05-01 Amicus Therapeutics Inc Formulations that include recombinant acid alpha-glucosidase
MX2018011951A (es) * 2016-03-30 2019-02-13 Amicus Therapeutics Inc Metodo para seleccionar proteinas recombinantes ricas en m6p.
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
IL319481A (en) 2016-09-12 2025-05-01 Inst Nat Sante Rech Med Variants of acid alpha-glucosidase and their uses
EP3624831B1 (en) 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
EP3635009A1 (en) 2017-06-07 2020-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
KR101942093B1 (ko) * 2018-01-05 2019-01-24 인하대학교 산학협력단 만노시다제 억제제를 포함하는 고만노즈 타입 n-당쇄를 갖는 인간 리소좀 효소 생산용 조성물
IL322464A (en) 2018-02-07 2025-09-01 Regeneron Pharma Methods and compositions for administering therapeutic protein
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
EP3996696A1 (en) 2019-07-09 2022-05-18 Genethon Treatment of glycogen storage disease (gsd)
WO2021102107A1 (en) * 2019-11-19 2021-05-27 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
EP2147681A1 (en) 1997-10-29 2010-01-27 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
AU3113700A (en) * 1998-12-07 2000-06-26 Genzyme Corporation Treatment of pompe's disease
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
CA2453978C (en) 2001-07-16 2011-10-11 Genzyme Corporation Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
AU2002348261A1 (en) 2001-11-26 2003-06-10 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
WO2004064750A2 (en) * 2003-01-22 2004-08-05 Duke University Improved constructs for expressing lysosomal polypeptides
US20100196345A1 (en) 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
DK2332972T3 (en) 2003-06-24 2018-04-23 Genzyme Corp Hitherto UNKNOWN BETA-ACTIN AND RPS21 PROMOTORS AND APPLICATIONS
CN1922313B (zh) * 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
WO2008063511A2 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
EP2465542B1 (en) 2008-12-16 2015-01-21 Genzyme Corporation Oligosaccharide-protein conjugates
WO2010096369A1 (en) * 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof

Also Published As

Publication number Publication date
MX2013012345A (es) 2015-05-07
WO2012145644A1 (en) 2012-10-26
BR112013026976A2 (pt) 2019-09-24
RU2013151875A (ru) 2015-05-27
CA2833371A1 (en) 2012-10-26
CO6811810A2 (es) 2013-12-16
PH12013502149A1 (en) 2019-09-02
AU2012245280A1 (en) 2013-11-07
MA35125B1 (fr) 2014-05-02
EP2699676A1 (en) 2014-02-26
TN2013000427A1 (en) 2015-03-30
PE20140617A1 (es) 2014-05-28
JP2017035091A (ja) 2017-02-16
KR20140037082A (ko) 2014-03-26
NI201300110A (es) 2014-02-28
ZA201307696B (en) 2014-07-30
CN103797115A (zh) 2014-05-14
SG10201605874TA (en) 2016-09-29
ECSP13013036A (es) 2015-04-30
CL2013003010A1 (es) 2014-03-07
GT201300252A (es) 2015-02-09
US20140186326A1 (en) 2014-07-03
SG194486A1 (en) 2013-12-30
JP2014513952A (ja) 2014-06-19
CR20130555A (es) 2013-12-09

Similar Documents

Publication Publication Date Title
ZA201307696B (en) Modified acid alpha glucosidase with accelerated processing
ZA201704649B (en) Processing biomass
ZA201704768B (en) Biomass processing
AP4052A (en) Processing biomass
AP4067A (en) Processing biomass
IL230511A0 (en) 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
HRP20190420T1 (hr) Postupci proizvodnje akrilne kiseline
PL2392523T3 (pl) Regał z rolkami centrującymi
EP2695133A4 (en) IDENTIFICATION OF SIMILARITIES
HK1195333A (en) Modified acid alpha glucosidase with accelerated processing
GB201102060D0 (en) Object detection with reduced compulation
PT2734522T (pt) 4-imidazopiridazina-1-il-benzamidas e 4-imidazotriazin-1- il-benzamidas como inibidores de btk